Loading...
MTAA
PHN
Market cap508mUSD
Jul 28, Last price  
45.50EUR
1D
-0.98%
1Q
-13.66%
IPO
228.52%
Name

Pharmanutra SpA

Chart & Performance

D1W1MN
No data to show
P/E
26.42
P/S
3.76
EPS
1.72
Div Yield, %
1.87%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
16.76%
Revenues
117m
+15.59%
26,254,66432,998,46937,784,56446,672,50353,811,00058,480,00068,578,00083,394,000101,034,000116,788,000
Net income
17m
+29.43%
2,571,9333,850,8386,030,4898,557,4978,454,00014,072,00013,771,00015,048,00012,832,00016,609,000
CFO
21m
+69.54%
05,861,3865,706,2876,436,10011,983,00011,791,00020,413,00014,466,00012,092,00020,501,000
Dividend
May 06, 20240.85 EUR/sh

Profile

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
URL
https://www.pharmanutra.it/
IPO date
Jul 18, 2017
Employees
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
116,788
15.59%
101,034
21.15%
83,394
21.60%
Cost of revenue
65,095
75,803
84,899
Unusual Expense (Income)
NOPBT
51,693
25,231
(1,505)
NOPBT Margin
44.26%
24.97%
Operating Taxes
10,610
10,428
8,370
Tax Rate
20.53%
41.33%
NOPAT
41,083
14,803
(9,875)
Net income
16,609
29.43%
12,832
-14.73%
15,048
9.27%
Dividends
(8,172)
(7,714)
(6,852)
Dividend yield
1.56%
1.41%
1.14%
Proceeds from repurchase of equity
(645)
(1,651)
(2,331)
BB yield
0.12%
0.30%
0.39%
Debt
Debt current
4,764
4,585
3,616
Long-term debt
21,183
25,042
14,859
Deferred revenue
Other long-term liabilities
8,426
6,958
9,307
Net debt
10,323
4,297
(3,580)
Cash flow
Cash from operating activities
20,501
12,092
14,466
CAPEX
(4,251)
(13,249)
(23,157)
Cash from investing activities
(2,214)
(14,702)
(23,715)
Cash from financing activities
(21,592)
(516)
1,891
FCF
38,561
2,519
(22,742)
Balance
Cash
29,097
25,118
26,861
Long term investments
(13,473)
212
(4,806)
Excess cash
9,785
20,278
17,885
Stockholders' equity
17,765
54,407
68,358
Invested Capital
85,108
69,102
58,572
ROIC
53.28%
23.19%
ROCE
54.48%
28.23%
EV
Common stock shares outstanding
9,609
9,668
9,672
Price
54.40
-3.55%
56.40
-9.47%
62.30
-17.37%
Market cap
522,735
-4.13%
545,255
-9.51%
602,573
-17.45%
EV
533,091
549,552
598,993
EBITDA
55,622
27,648
(361)
EV/EBITDA
9.58
19.88
Interest
1,062
802
60
Interest/NOPBT
2.05%
3.18%